EDTXFSpectral Medical Inc.

About Spectral Medical Inc. (EDTXF)

Spectral Medical Inc. (EDTXF) is a Diagnostics & Research company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the Pink tier.

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

EDTXF key facts

Ticker symbol

EDTXF

Market tier

Pink

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Toronto, ON, Canada

Country of incorporation

DE

Year of incorporation

1991

Employees

16

Estimated market cap

$139.53M (as of Apr 10, 2025)

Shares outstanding

285,117,225

Reporting standard

International Reporting: Toronto Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Sep 30, 2016)

Spectral Medical Inc. leadership

• Paul M. Walker — President, CEO
• Anthony Businskas — EVP, CFO, IR
• Debra M. Foster — VP, Clinical Development

Explore more: Diagnostics & Research stocks · Healthcare sector · Pink stocks · OTC stocks starting with E